Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651925 | 0.93 | MAPK1 (0.50) | NAPRTPOLBPKMRAB9ASMN1; SMN2 | |
| SCHEMBL2660622 | 0.84 | HSD17B3 (0.43) | NAPRTPOLBPKMDGAT1RAB9A | |
| SCHEMBL333999 | 0.82 | NAPRT (0.60) | NAPRTPOLBPKMDGAT1RAB9A | |
| SCHEMBL31606802 | 0.82 | NAPRT (0.60) | NAPRTPOLBPKMDGAT1RAB9A | |
| SCHEMBL1436840 | 0.81 | HDAC1 (0.50) | POLBMLYCDL3MBTL1MAPTKMT2A | |
| SCHEMBL2253612 | 0.81 | MLYCD (0.46) | MLYCDSMN1; SMN2L3MBTL1MAPTKMT2A | |
| SCHEMBL2571770 | 0.80 | MLYCD (0.49) | MLYCDL3MBTL1KMT2A | |
| SCHEMBL15003978 | 0.80 | MLYCD (0.45) | MLYCDL3MBTL1KMT2AMEN1 | |
| SCHEMBL15057209 | 0.80 | NNMT (0.53) | MLYCDSMN1; SMN2 | |
| SCHEMBL5775763 | 0.80 | MLYCD (0.45) | MLYCDL3MBTL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027029-A | Preparation method and application of Anfonafate and analogues thereof | 新疆大学 | 2024-05-14 | — | — | CN | claimed |
| CN-118027029-A | Preparation method and application of Anfonafate and analogues thereof | 新疆大学 | 2024-05-14 | — | — | CN | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
| EP-3952914-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) | 2022-02-16 | — | — | EP | disclosed |
| CN-113924123-A | Methods and compositions for targeted protein degradation | 珃诺生物医药科技(杭州)有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3097101-B1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3097101-B1 | ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-0607193-B1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER LTD (GB) | 2000-09-13 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6015825-A | Triazole antifungal agents | PFIZER INC. (US) | 2000-01-18 | — | — | US | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0835252-A1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997001552-A1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-01-16 | — | — | WO | disclosed |
| US-5541203-A | PREVENTING OR CURING FUNGAL INFECTIONS | PFIZER INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995003306-A1 | ARTHROPODICIDAL AZACYCLIC HETEROCYCLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-02-02 | — | — | WO | disclosed |
| EP-0607193-A1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Limited (GB) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007139-A1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER LIMITED (GB) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, RPS27A, HSPBP1 | NAPRT 2884/4885POLB 3383/4885PKM 3452/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | NAPRT 1139/4885POLB 4044/4885PKM 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.